Fulcrum Therapeutics to Participate in the Goldman Sachs’ 45th Annual Global Healthcare Conference

Rhea-AI Summary

Fulcrum Therapeutics, a clinical-stage biopharmaceutical company, announced its participation in Goldman Sachs’ 45th Annual Healthcare Conference. Scheduled for June 10, 2024, at 10:00 a.m. ET, the company's management will engage in a fireside chat. A webcast of the presentation will be accessible via Fulcrum's website and available for replay for at least 30 days post-event. Fulcrum focuses on developing small molecules aimed at improving the lives of patients with genetically defined rare diseases.

Positive

• Participation in a prestigious event like Goldman Sachs’ Annual Healthcare Conference enhances visibility.
• Webcast and replay availability can attract more investor attention and shareholder engagement.

Negative

• No immediate business development or financial data provided.
• Lack of detailed information on clinical trial progress or new product announcements.

CAMBRIDGE, Mass., June 06, 2024 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.^® (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced that management will participate in a fireside chat at Goldman Sachs’ 45^th Annual Healthcare Conference on Monday, June 10^th, 2024, at 10:00 a.m. ET.

The webcast of the presentation will be accessible here and by visiting the "Events and Presentations" section of Fulcrum Therapeutics’ website at https://ir.fulcrumtx.com/events-and-presentations. A replay of the webcast will be available on Fulcrum Therapeutics’ website for at least 30 days following the presentation.

About Fulcrum Therapeutics
Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases in areas of high unmet medical need. Fulcrum’s two lead programs in clinical development are losmapimod, a small molecule in development for the treatment of facioscapulohumeral muscular dystrophy (FSHD), and pociredir, a small molecule designed to increase expression of fetal hemoglobin and in development for the treatment of sickle cell disease (SCD) and other hemoglobinopathies. Fulcrum uses proprietary technology to identify drug targets that can modulate gene expression to treat the known root cause of gene mis-expression. For more information, visit www.fulcrumtx.com and follow us on Twitter/X (@FulcrumTx) and LinkedIn.

Contact:
Chris Calabrese
LifeSci Advisors, LLC
ccalabrese@lifesciadvisors.com
917-680-5608

FAQ

What event is Fulcrum Therapeutics participating in on June 10, 2024?

Fulcrum Therapeutics is participating in Goldman Sachs’ 45th Annual Healthcare Conference.

When will Fulcrum Therapeutics' fireside chat at the Goldman Sachs’ Healthcare Conference take place?

The fireside chat will take place on June 10, 2024, at 10:00 a.m. ET.

How can I access the webcast of Fulcrum Therapeutics’ presentation at the Goldman Sachs’ Healthcare Conference?

The webcast will be accessible through Fulcrum Therapeutics’ website by visiting the 'Events and Presentations' section.

Will a replay of Fulcrum Therapeutics’ presentation at the Goldman Sachs’ Healthcare Conference be available?

Yes, a replay will be available on Fulcrum Therapeutics’ website for at least 30 days following the presentation.

What is the focus of Fulcrum Therapeutics' research and development?

Fulcrum Therapeutics focuses on developing small molecules to improve the lives of patients with genetically defined rare diseases.